Phase II trial of bendamustine plus rituximab treatment for relapsed or refractory low grade B-cell non Hodgkin lymphoma
Phase 2
- Conditions
- relapsed or refractory follicular lymphoma
- Registration Number
- JPRN-UMIN000005386
- Lead Sponsor
- Kanagawa Clinical Oncology study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 44
Inclusion Criteria
Not provided
Exclusion Criteria
1: pregnancy or breast feeding 2: any other malignancy 3: mental illness 4: positive test for HBV surface antigen 5: positive test for HCV anti body 6: positive test for HIV anti body 7: lymphoma cell count > 25 x 10*9/L in peripheral blood 8: post allogenic stem cell transplantation 9: interstitial pneumonia or pulmonary fibrosis 10: central nervous system involvement with lymphoma 11: history of bendamustine treatment 12: inappropriate for rituximab treatment 13: severe hypersensitivity for any drugs 14: inappropriate for entry by physician's decision
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method